Skip to menu Skip to content Skip to footer
Associate Professor

Colm Keane

Email: 
Phone: 
+61 7 344 37912

Overview

Background

Dr Keane is a haematologist at Princess Alexandra Hospital and runs the Lymphoma Research Lab at the UQDI in Brisbane. His main research interest is focused on the interface between the tumour microenvironment and the malignant lymphoma cell, with a goal to build an understanding of lymphoma from an immunological and biomarkers perspective. To bridge developments between the clinic and bench-top, the laboratory has a strong emphasis on patient material, which it obtains from international and national clinical collaborators, much being from investigator-led clinical trials.

Lymphomas studied include more common lymphomas such as Hodgkin Lymphoma, Diffuse Large B-cell Lymphoma and Follicular Lymphoma but his lab has a particular focus on rare lymphomas such as primary central nervous system lymphoma and lymphomas that develop in patients who are immunocompromised.

Dr. Keane has been instrumental in translating work from his lab into multiple immune based clinical trials currently being run across Australia, many in rare and hard to treat lymphomas, where patients have limited treatments available.

The goals of the lab are to directly improve outcomes for all lymphoma patients by performing innovative translational science that not only generates new knowledge and brings new treatments to Australian patients but helps to train the next generation of lymphoma researchers in Australia.

Availability

Associate Professor Colm Keane is:
Available for supervision

Qualifications

  • Masters (Coursework) of Business Administration, Griffith University
  • Doctor of Philosophy, Griffith University

Research interests

  • Tumour Immunology

  • DLBCL

  • Primary CNS Lymphoma

  • Hodgkin Lymphoma

  • Viral Associated Lymphomas

Works

Search Professor Colm Keane’s works on UQ eSpace

129 works between 2004 and 2024

101 - 120 of 129 works

2015

Conference Publication

Pre-treatment circulating tumor DNA as a biomarker for disease burden in diffuse large B cell lymphoma (DLBCL)

Scherer, Florian, Kurtz, David Matthew, Green, Michael Richard, Newman, Aaron M., Klass, Daniel M., Zhou, Li, Krishnan, Rashi, Liu, Chih Long, Glover, Cynthia, Ohgami, Robert S., Hicks, Rodney J., Keane, Colm, Kong, Katherine A., Faham, Malek, Hertzberg, Mark S., Gandhi, Maher K., Advani, Ranjana H., Levy, Ronald, Diehn, Maximilian and Alizadeh, Ash A. (2015). Pre-treatment circulating tumor DNA as a biomarker for disease burden in diffuse large B cell lymphoma (DLBCL). Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, United States, May 29-June 2, 2015. Alexandria, United States: American Society of Clinical Oncology.

Pre-treatment circulating tumor DNA as a biomarker for disease burden in diffuse large B cell lymphoma (DLBCL)

2014

Journal Article

A comprehensive analysis of the cellular and EBV-Specific MicroRNAome in primary CNS PTLD identifies different patterns among EBV-associated tumors

Fink, S. E. K., Gandhi, M. K., Nourse, J. P., Keane, C., Jones, K., Crooks, P., Johrens, K., Korfel, A., Schmidt, H., Neumann, S., Tiede, A., Jager, U., Duhrsen, U., Neuhaus, R., Dreyling, M., Borchert, K., Sudhoff, T., Riess, H., Anagnostopoulos, I. and Trappe, R. U. (2014). A comprehensive analysis of the cellular and EBV-Specific MicroRNAome in primary CNS PTLD identifies different patterns among EBV-associated tumors. American Journal of Transplantation, 14 (11), 2577-2587. doi: 10.1111/ajt.12858

A comprehensive analysis of the cellular and EBV-Specific MicroRNAome in primary CNS PTLD identifies different patterns among EBV-associated tumors

2014

Journal Article

Plasma microRNA are disease response biomarkers in classical Hodgkin lymphoma

Jones, Kimberley, Nourse, Jamie P., Keane, Colm, Bhatnagar, Atul and Gandhi, Maher K. (2014). Plasma microRNA are disease response biomarkers in classical Hodgkin lymphoma. Clinical Cancer Research, 20 (1), 253-264. doi: 10.1158/1078-0432.CCR-13-1024

Plasma microRNA are disease response biomarkers in classical Hodgkin lymphoma

2014

Conference Publication

Noninvasive monitoring of cellular versus acellular tumor DNA from immunoglobulin genes for DLBCL

Kurtz, David Matthew, Green, Michael R., Bratman, Scott Victor, Liu, Chih-Long, Glover, Cynthia, Keane, Colm, Kong, Katie, Faham, Malek, Miklos, David Bernard, Advani, Ranjana H., Levy, Ronald, Hertzberg, Mark S., Gandhi, Maher K., Diehn, Maximilian and Alizadeh, Ash A. (2014). Noninvasive monitoring of cellular versus acellular tumor DNA from immunoglobulin genes for DLBCL. 50th Annual Meeting of the American Society of Clinical Oncology, Chicago IL United States, May 30-June 3, 2014. Alexandria VA, United States: American Society of Clinical Oncology.

Noninvasive monitoring of cellular versus acellular tumor DNA from immunoglobulin genes for DLBCL

2013

Journal Article

CD4+Tumor infiltrating lymphocytes are prognostic and independent of R-IPI in patients with DLBCL receiving R-CHOP chemo-immunotherapy

Keane, Colm, Gill, Devinder, Vari, Frank, Cross, Donna, Griffiths, Lynn and Gandhi, Maher (2013). CD4+Tumor infiltrating lymphocytes are prognostic and independent of R-IPI in patients with DLBCL receiving R-CHOP chemo-immunotherapy. American Journal of Hematology, 88 (4), 273-276. doi: 10.1002/ajh.23398

CD4+Tumor infiltrating lymphocytes are prognostic and independent of R-IPI in patients with DLBCL receiving R-CHOP chemo-immunotherapy

2013

Journal Article

Serum CD163 and TARC as disease response biomarkers in classical Hodgkin lymphoma

Jones, Kimberley, Vari, Frank, Keane, Colm, Crooks, Pauline, Nourse, Jamie P., Seymour, Louise A., Gottlieb, David, Ritchie, David, Gill, Devinder and Gandhi, Maher K. (2013). Serum CD163 and TARC as disease response biomarkers in classical Hodgkin lymphoma. Clinical Cancer Research, 19 (3), 731-742. doi: 10.1158/1078-0432.CCR-12-2693

Serum CD163 and TARC as disease response biomarkers in classical Hodgkin lymphoma

2013

Journal Article

High-resolution loss of heterozygosity screening implicates PTPRJ as a potential tumor suppressor gene that affects susceptibility to non-hodgkin's lymphoma

Aya-Bonilla, C., Green, M.R., Camilleri, E., Benton, M., Keane, C., Marlton, P., Lea, R., Gandhi, M.K. and Griffiths, L.R. (2013). High-resolution loss of heterozygosity screening implicates PTPRJ as a potential tumor suppressor gene that affects susceptibility to non-hodgkin's lymphoma. Genes Chromosomes and Cancer, 52 (5), 467-479. doi: 10.1002/gcc.22044

High-resolution loss of heterozygosity screening implicates PTPRJ as a potential tumor suppressor gene that affects susceptibility to non-hodgkin's lymphoma

2012

Journal Article

Homozygous FCGR3A-158V alleles predispose to late onset neutropenia after CHOP-R for diffuse large B-cell lymphoma

Keane, C., Nourse, J. P., Crooks, P., Nguyen-Van, D., Mutsando, H., Mollee, P., Lea, R. A. and Gandhi, M. K. (2012). Homozygous FCGR3A-158V alleles predispose to late onset neutropenia after CHOP-R for diffuse large B-cell lymphoma. Internal Medicine Journal, 42 (10), 1113-1119. doi: 10.1111/j.1445-5994.2011.02587.x

Homozygous FCGR3A-158V alleles predispose to late onset neutropenia after CHOP-R for diffuse large B-cell lymphoma

2012

Journal Article

Expression profiling of Epstein-Barr virus-encoded microRNAs from paraffin-embedded formalin-fixed primary Epstein-Barr virus-positive B-cell lymphoma samples

Nourse, J.P., Crooks, P., Keane, C.., Nguyen-Van, D., Mujaj, S., Ross, N., Jones, K., Vari, F., Han, E., Trappe, R., Fink, S. and Gandhi, M.K. (2012). Expression profiling of Epstein-Barr virus-encoded microRNAs from paraffin-embedded formalin-fixed primary Epstein-Barr virus-positive B-cell lymphoma samples. Journal of Virological Methods, 184 (1-2), 46-54. doi: 10.1016/j.jviromet.2012.05.005

Expression profiling of Epstein-Barr virus-encoded microRNAs from paraffin-embedded formalin-fixed primary Epstein-Barr virus-positive B-cell lymphoma samples

2012

Journal Article

Valproic acid combined with cytosine arabinoside in elderly patients with acute myeloid leukemia has in vitro but limited clinical activity

Lane, Steven, Gill, Devinder, McMillan, Nigel A. J., Saunders, Nicholas, Murphy, Rachel, Spurr, Terrence, Keane, Colm, Fan, Helen Mar and Mollee, Peter (2012). Valproic acid combined with cytosine arabinoside in elderly patients with acute myeloid leukemia has in vitro but limited clinical activity. Leukemia & Lymphoma, 53 (6), 1077-1083. doi: 10.3109/10428194.2011.642302

Valproic acid combined with cytosine arabinoside in elderly patients with acute myeloid leukemia has in vitro but limited clinical activity

2012

Journal Article

Tumor-specific but not nonspecific cell-free circulating DNA can be used to monitor disease response in lymphoma

Jones, Kimberley, Nourse, Jamie P., Keane, Colm, Crooks, Pauline, Gottlieb, David, Ritchie, David S., Gill, Devinder and Gandhi, Maher K. (2012). Tumor-specific but not nonspecific cell-free circulating DNA can be used to monitor disease response in lymphoma. American Journal of Hematology, 87 (3), 258-265. doi: 10.1002/ajh.22252

Tumor-specific but not nonspecific cell-free circulating DNA can be used to monitor disease response in lymphoma

2012

Conference Publication

Serum CD163 and TARC in Combination As Disease Response Biomarkers in Classical Hodgkin Lymphoma

Gandhi, Maher K., Vari, Frank, Crooks, Pauline, Keane, Colm, Nourse, Jamie P., Seymour, Louise A., Ritchie, David, Gottlieb, David, Gill, Devinder and Jones, Kimberley (2012). Serum CD163 and TARC in Combination As Disease Response Biomarkers in Classical Hodgkin Lymphoma. 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Atlanta GA, United States, 8-11 December 2012. Washington, DC United States: American Society of Hematology.

Serum CD163 and TARC in Combination As Disease Response Biomarkers in Classical Hodgkin Lymphoma

2012

Book Chapter

Rituximab induced late-onset neutropenia

Keane, Colm, Nourse, Jamie P. and Gandhi, Maher K. (2012). Rituximab induced late-onset neutropenia. Rituximab: Pharmacology, Clinical Uses and Health Effects. (pp. 93-102) Hauppauge, NY United States: Nova Science Publishers.

Rituximab induced late-onset neutropenia

2011

Journal Article

Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly expresses EBNA3A with conserved CD8 T-cell epitopes

Nguyen-Van, Do, Keane, Colm, Han, Erica, Jones, Kimberley, Nourse, Jamie P., Vari, Frank, Ross, Nathan, Crooks, Pauline, Ramuz, Olivier, Green, Michael, Griffith, Lyn, Trappe, Ralf, Grigg, Andrew, Mollee, Peter and Gandhi, Maher K. (2011). Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly expresses EBNA3A with conserved CD8 T-cell epitopes. American Journal of Blood Research, 1 (2), 146-159.

Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly expresses EBNA3A with conserved CD8 T-cell epitopes

2011

Conference Publication

Tissue Microarray in DLBCL Patients receiving R-CHOP Chemo-Immunotherapy Shows Survival Benefit for Coexpression of LMO2/BCL6

Keane, C, Shen, L, Han, E, Nourse, JP, Lea, R, Mollee, P, Gill, DS and Gandhi, MK (2011). Tissue Microarray in DLBCL Patients receiving R-CHOP Chemo-Immunotherapy Shows Survival Benefit for Coexpression of LMO2/BCL6. 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), San Diego Ca, Dec 10-13, 2011. WASHINGTON: AMER SOC HEMATOLOGY.

Tissue Microarray in DLBCL Patients receiving R-CHOP Chemo-Immunotherapy Shows Survival Benefit for Coexpression of LMO2/BCL6

2011

Journal Article

Treatment of acute promyelocytic leukaemia in the Jehovah's Witness population

Keane, Colm, Mollee, Peter, Marlton, Paula and Gill, Devinder (2011). Treatment of acute promyelocytic leukaemia in the Jehovah's Witness population. Annals of Hematology, 90 (3), 359-360. doi: 10.1007/s00277-010-1023-0

Treatment of acute promyelocytic leukaemia in the Jehovah's Witness population

2011

Conference Publication

Monocytes Are Associated with Impaired T-Cell Immunity and Residual Interim-PET/CT Avidity After 4 Cycles of CHOP-R In Patients with High-Risk DLBCL

Gandhi, MK, Hertzberg, MS, Han, E, Seymour, JF, Hicks, R, Gill, DS, Keane, C, Crooks, P, Radford, K and Vari, F (2011). Monocytes Are Associated with Impaired T-Cell Immunity and Residual Interim-PET/CT Avidity After 4 Cycles of CHOP-R In Patients with High-Risk DLBCL. 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), San Diego Ca, Dec 10-13, 2011. WASHINGTON: AMER SOC HEMATOLOGY.

Monocytes Are Associated with Impaired T-Cell Immunity and Residual Interim-PET/CT Avidity After 4 Cycles of CHOP-R In Patients with High-Risk DLBCL

2011

Conference Publication

Tissue microarray in DLBCL patients receiving CHOP-R chemo-immunotherapy shows survival benefit for coexpression of LMO2/BCL6 and poor outcome for EBER-ISH positive patients

Keane, C., Shen, L., Nourse, J., Han, E., Jones, K. and Gandhi, M. (2011). Tissue microarray in DLBCL patients receiving CHOP-R chemo-immunotherapy shows survival benefit for coexpression of LMO2/BCL6 and poor outcome for EBER-ISH positive patients. 11th International Conference on Malignant Lymphoma, Lugano, Switzerland, 15-18 June 2011. Oxford, United Kingdom: Oxford University Press.

Tissue microarray in DLBCL patients receiving CHOP-R chemo-immunotherapy shows survival benefit for coexpression of LMO2/BCL6 and poor outcome for EBER-ISH positive patients

2010

Conference Publication

Ebv-Positive Dlbcl of the Elderly Is a Distinct Clinico-Biological Entity with Poor Outcome in Chop-R Treated Patients

Gandhi, M., Keane, C., Nourse, J., Jones, K., Ross, N., Han, E. and Nguyen-Van, D. (2010). Ebv-Positive Dlbcl of the Elderly Is a Distinct Clinico-Biological Entity with Poor Outcome in Chop-R Treated Patients. 15th Annual Meeting of the European-Hematology-Association, Barcelona Spain, June 10-13, 2010. Pavia, Italy: Fondazione Ferrata Storti.

Ebv-Positive Dlbcl of the Elderly Is a Distinct Clinico-Biological Entity with Poor Outcome in Chop-R Treated Patients

2009

Journal Article

Myeloid and lymphoid neoplasm with FGFR1 abnormality

Keane, Colm, Henden, Andrea, Mills, Tony and Wood, Peter (2009). Myeloid and lymphoid neoplasm with FGFR1 abnormality. British Journal of Haematology, 145 (4), 440-440. doi: 10.1111/j.1365-2141.2008.07480.x

Myeloid and lymphoid neoplasm with FGFR1 abnormality

Funding

Current funding

  • 2024 - 2029
    BrainCAR19 Study- Treatment of relapsed Primary Brain Lymphoma with CD19 directed CAR-T cells
    NHMRC MRFF CTA - Clinical Trials Activity
    Open grant
  • 2022 - 2027
    An early phase, open label, multi-centre trial of front-line TheRapy for EBv-associated Lymphomas -- 2: TREBL-2 (Stream 6)
    NHMRC MRFF - Rare Cancers, Rare Diseases and Unmet Need
    Open grant
  • 2021 - 2026
    Investigation of Immune evasion in relapsed lymphoma (RADD Trial) (Victorian Cancer Agency Translational Research Project administered by La Trobe University)
    Olivia Newton-John Cancer Research Institute
    Open grant
  • 2021 - 2025
    Employing rational novel agent combination therapy to improve transplant cure rates for relapsed/refractory Hodgkin Lymphoma (MRFF RCRDUN administered by La Trobe University)
    La Trobe University
    Open grant
  • 2021 - 2025
    Immuno-genetic biomarkers of response in a prospective study of immune checkpoint therapy in primary CNS lymphoma
    NHMRC MRFF Investigator Grant
    Open grant
  • 2019 - 2026
    An Open Label, Multicentre, Phase One Study Incorporating Early Application of CAR T cells for Primary Refractory Aggressive Lymphoma
    NHMRC MRFF - Rare Cancers, Rare Diseases and Unmet Need
    Open grant
  • 2018 - 2025
    An Open label, Multicentre, Phase I study of Ibrutinib, Rituximab and EBV specific T-cells in Patients with EBV-positive Primary or Secondary CNS Lymphoma unsuitable for standard therapies
    NHMRC MRFF - Lifting Clinical Trials Registries Capacity
    Open grant

Past funding

  • 2021 - 2024
    ALLGNHL32 Study - An ALLG Phase II study of pembrolizumab checkpoint blockade following chemoimmunotherapy for primary central nervous system lymphoma
    Australasian Leukaemia & Lymphoma Group
    Open grant
  • 2020 - 2023
    Novel immune based approaches to improve survival for patients with Primary Central Nervous Lymphoma
    Queensland Advancing Clinical Research Fellowship
    Open grant
  • 2019 - 2020
    Investigation of the key immuno-genetic drivers of Primary Central Nervous System Lymphoma that occurs in patients with HIV infection
    Cancer Australia
    Open grant
  • 2017 - 2020
    Investigation of unique immune microenvironment of Primary CNS Lymphoma
    NHMRC Early Career Fellowships
    Open grant
  • 2017 - 2019
    The prognostic utility of the tumour microenvironment in Non-Hodgkin's Lymphoma
    Celgene Pty Ltd
    Open grant
  • 2016 - 2017
    Does lymphoma avoid immune destruction by inducing T-cell tolerance?
    Cancer Council Queensland
    Open grant
  • 2015 - 2018
    A correlative laboratory study of primary CNS lymphoma
    Research Donation Generic
    Open grant
  • 2015 - 2018
    Net tumoral immunity and its impact on outcome in lymphoma
    The Leukaemia Foundation of Australia Limited
    Open grant

Supervision

Availability

Associate Professor Colm Keane is:
Available for supervision

Before you email them, read our advice on how to contact a supervisor.

Supervision history

Current supervision

Completed supervision

Media

Enquiries

For media enquiries about Associate Professor Colm Keane's areas of expertise, story ideas and help finding experts, contact our Media team:

communications@uq.edu.au